Stay updated with breaking news from Pascal Deschatelets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apellis Pharmaceuticals (NASDAQ: APLS) has recently received a number of price target changes and ratings updates: 8/30/2023 – Apellis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock. 8/29/2023 – Apellis Pharmaceuticals had its price target raised by analysts at Citigroup […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a note issued to investors on Wednesday, Benzinga reports. They presently have a $60.00 price target on the stock. Needham & Company LLC’s target price suggests a potential upside of 42.15% from the […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target boosted by investment analysts at Stifel Nicolaus from $60.00 to $65.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 60.06% from the company’s […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective raised by research analysts at Citigroup from $45.00 to $54.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 32.97% from the company’s current price. […]
Nicholas Investment Partners LP raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 35.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 336,951 shares of the company’s stock after purchasing an additional 88,668 shares during the period. Apellis Pharmaceuticals […]